课题基金 / 基金详情

Investigation of biological effects of IDH gene mutation in malignant glioma

Investigation of biological effects of IDH gene mutation in malignant glioma
IDH基因突变对恶性胶质瘤的生物学效应研究
批准号:
23791614
负责人:
TANAKA Masaki
金额:
$2.75万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Young Scientists (B)
财政年份:
2011
资助国家:
日本
项目状态:
已结题
起止时间:
2011 至 2013

项目摘要

项目成果

TANAKA Masaki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We investigated biological effects of glioma-related genetic alteration, IDH1 gene mutation, in human glioma cells. The IDH1R132H gene was introduced into highly transformed glioblastoma cells by transfection, and the cells overexpressing IDH1R132H were selected by G418 treatment. These cells did not exhibit significant changes in expression of tumor-, apoptosis-, or cell cycle-related genes, but were rather sensitive to CDDP treatment. Xenografts in athymic mice derived from these cells grew slower than parental cells. These results suggested that IDH1 mutation which is a hallmark of representative genetic alterations in lower grade glioma might bestow negative impact on aggressive behavior of higher grade gliomas.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
今日の治療と看護 改訂第3版
今日治疗与护理修订版第三版
DOI: --
发表时间: 2013
期刊:
影响因子: --
作者: [Ota I, Higashiyama S, Masui T, et al., 兵頭政光]
通讯作者: 兵頭政光
Bevacizumab monotherapy for recurrent malignant glioma ---Efficacy and prediction of response ---
贝伐珠单抗单药治疗复发性恶性胶质瘤——疗效和反应预测——
DOI: --
发表时间: 2012
期刊:
影响因子: --
作者: [Nagane M, Tanaka M, 他4名]
通讯作者: 他4名
Combination treatment with the anti-EGFR monoclonal antibody, nimotuzumab, and temozolomide causes synergistic growth suppression of mutant EGFR expressing glioma xenografts
抗 EGFR 单克隆抗体、尼妥珠单抗和替莫唑胺的联合治疗可导致表达突变型 EGFR 的神经胶质瘤异种移植物的协同生长抑制
DOI: --
发表时间: 2013
期刊: Proceedings of 104th Annual Meeting of the American Association for Cancer Research
影响因子: --
作者: [Nagane M, Nitta Y, Shimizu S, Shishido-Hara Y, Shiokawa Y]
通讯作者: Shiokawa Y
Multidrug immunochemotherapy (R-MPV-A) for newly diagnosed and recurrent primary central nervous system lymphomas.
用于新诊断和复发的原发性中枢神经系统淋巴瘤的多药免疫化疗(R-MPV-A)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: [Motoo Nagane, Keiichi Kobayashi, Nobuyuki Takayama, Yoshiaki Shiokawa]
通讯作者: Yoshiaki Shiokawa
10
    Development of wide scanning angle for millimeter wave beam by liquid crystal quasi-optical device with subwavelength structure
    • 批准号:
      26390107
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.16万
    • 财政年份:
      2014
    • 负责人:
      TANAKA Masaki
    • 依托单位:
    For the in vivo imaging of 5-HT2C receptor activity using Tango system
    • 批准号:
      25640024
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2013
    • 负责人:
      TANAKA Masaki
    • 依托单位:
    Involvement of RNA editing of 5HT2C receptor in emotion and stress: functional and morphological study
    • 批准号:
      25290014
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.07万
    • 财政年份:
      2013
    • 负责人:
      TANAKA Masaki
    • 依托单位:
    Development of a research technique to create animal model of brain lesions using therapeutic linear accelerator
    • 批准号:
      24650206
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2012
    • 负责人:
      TANAKA Masaki
    • 依托单位:
    国内基金
    海外基金
    NLRP3抑制Mito PYCR1促进 IDH1/2野生型胶质瘤焦亡诱发脑水肿机制研究
    • 批准号:
      2026JJ82626
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      唐慧
    • 依托单位:
    GADD45B诱导IDH1降解促进心肌细胞铁死亡介导脓毒症心肌病发生发展的作用及机制研究
    • 批准号:
      2026JJ60291
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      周阳
    • 依托单位:
    葡萄糖剥夺通过抑制IDH1和H3K9乳酸化修饰诱导仑伐替尼耐药肝细胞癌双硫死亡的机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      唐陈伟
    • 依托单位:
    基于IDH1琥珀酰化修饰调控 CXCL12/CXCR4轴探讨驻车丸防治肠炎相 关结直肠癌的作用及机制
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      10.0万元
    • 批准年份:
      2025
    • 负责人:
      张晓君
    • 依托单位: